Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

alrestatin

Known as: 1,3-dioxo-1H-benz(de)isoquinoline-2(3H)- acetate, AY22,284 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Diabetes mellitus occurrence has been associated to the modification of the physiological levels of glucose and is often… Expand
1997
1997
It is generally expected that only one inhibitor molecule will bind to an enzyme active site. In fact, specific drug design… Expand
Highly Cited
1994
Highly Cited
1994
Aldose reductase enfolds NADP+/NADPH via a complex loop mechanism, with cofactor exchange being the rate-limiting step for the… Expand
Highly Cited
1991
Highly Cited
1991
A variety of 2,4-dioxoquinazolineacetic acids (10, 11) were synthesized as hybrids of the known aldose reductase inhibitors… Expand
Highly Cited
1990
Highly Cited
1990
A broad group of structurally diverse aldose reductase inhibitors including flavonoids, carboxylic acids and hydantoins, have… Expand
1982
1982
Abstract: Human brain aldose reductase and hexonate dehydrogenase are inhibited by alrestatin (AY 22,284) and sorbinil (CP 45,634… Expand
Highly Cited
1981
Highly Cited
1981
A single-blind, nonrandomized, placebo crossover clinical trial of an aldose reductase inhibitor, Alresta-tin (AY 22, 284) was… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Highly Cited
1981
Highly Cited
1981
The sorbitol pathway in human lenses is evaluated on the enzymic level. Adult lenses, normal and nondiabetic as well as diabetic… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
Highly Cited
1979
Highly Cited
1979
Studies with the aldose reductase inhibitor alrestatin in animal models have suggested that the sorbitol pathway may be of… Expand
1979
1979
Immediately after cataract extraction, lenses from diabetic and nondiabetic patients were collected, classified, and assayed or… Expand